More than 130 suppliers
ISO certified
In-house tech support
we Connect you
Bio-Connect
ProductsBack/(R)-CR8 [294646-77-8]
Chemical Structure
Chemical Structure
Chemical Structure

(R)-CR8 [294646-77-8]

Research Use Only
AG-MR-C0003
AdipoGen Life Sciences
CAS Number294646-77-8
DownloadMSDS
Product group Chemicals
Estimated Purity>98%
Molecular Weight431.5
Price on request
Packing Size
Large volume orders?
Order with a bulk request
More than 130 suppliers
ISO certified
In-house tech support

Overview

  • Supplier
    AdipoGen Life Sciences
  • Product Name
    (R)-CR8 [294646-77-8]
  • Delivery Days Customer
    10
  • CAS Number
    294646-77-8
  • Certification
    Research Use Only
  • Estimated Purity
    >98%
  • Hazard Information
    Warning
  • Molecular Formula
    C24H29N7O
  • Molecular Weight
    431.5
  • Scientific Description
    Chemical. CAS: 294646-77-8. Formula: C24H29N7O. MW: 431.5. Potent and selective inhibitor of cyclin dependent kinases CDK1, CDK2, CDK5, CDK7 and CDK9. Apoptosis inducer. Inhibits the proliferation of various cancer cell lines. Casein kinase 1 (CK1delta/epsilon) and glycogen synthase kinase (GSK-3alpha/beta) inhibitor. Potential anti-inflammatory compound. Potential antidiabetic compound. - Potent and selective inhibitor of cyclin dependent kinases CDK1, CDK2, CDK5, CDK7 and CDK9. Apoptosis inducer [1, 3, 4]. Inhibits the proliferation of various cancer cell lines [1]. Casein kinase 1 (CK1delta/epsilon) and glycogen synthase kinase (GSK-3alpha/beta) inhibitor [1, 2]. Potential anti-inflammatory compound. Potential antidiabetic compound.
  • SMILES
    CC[C@H](CO)NC1=NC2=C(N=CN2C(C)C)C(NCC2=CC=C(C=C2)C2=NC=CC=C2)=N1
  • Storage Instruction
    -20°C,2°C to 8°C
  • UNSPSC
    51202000

References

  • CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases: K. Bettayeb, et al.; Oncogene 27, 5797 (2008)
  • Roscovitine-derived, dual-specificity inhibitors of cyclin-dependent kinases and casein kinases 1: N. Oumata, et al.; J. Med. Chem. 51, 5229 (2008)
  • CDK Inhibitors Roscovitine and CR8 Trigger Mcl-1 Down-Regulation and Apoptotic Cell Death in Neuroblastoma Cells: K. Bettayeb, et al.; Genes Cancer 1, 369 (2010)
  • CR8, a selective and potent CDK inhibitor, provides neuroprotection in experimental traumatic brain injury. S.V. Kabadi, et al.; Neurotherapeutics 9, 405 (2012)
  • Inhibition of NF-kappaB-mediated signaling by the cyclin-dependent kinase inhibitor CR8 overcomes prosurvival stimuli to induce apoptosis in chronic lymphocytic leukemia cells: E. Cosimo, et al.; Clin. Cancer Res. 19, 2393 (2013)